Safety Issue Halts Study of BMS HCV Drug

(MedPage Today) — Bristol-Myers Squibb has suspended treatment “to protect patient safety” in a phase IIb trial of an investigational oral drug for hepatitis C.

Post a Comment

Comments are closed.